Vancouver, British Columbia (March 4, 2026) – Rise Nano Optics Ltd. (formerly Skylift Tech Ventures Ltd.) (“Rise” or the “Company”) is pleased to announce that it has obtained a final receipt for its final long form prospectus dated February 28, 2026 (the “Final Prospectus“) from the British Columbia Securities Commission and is now a reporting issuer in the province of British Columbia. No securities are being offered pursuant to the Final Prospectus, which was filed for the purpose of allowing Rise to become a reporting issuer in the province of British Columbia, allowing Rise to satisfy the listing requirements of the Canadian Securities Exchange (the “CSE“) and to satisfy certain closing conditions of the reverse takeover of the Company by Rise Nano Optics Ltd. (an Israeli company) (“Rise Israel”), a leading ophthalmic company focused on the development, commercialization and application of nanotechnology to eyewear and optical solutions that protect against harmful light wavelengths (the “RTO Transaction”). The RTO Transaction closed on March 4, 2026 and the Company issued 21,150,000 Common Shares (as defined below), 6,244,880 Warrants (as defined below) and 9,331,785 Contingent Rights (as defined below) to the shareholders of Rise Israel in consideration for the acquisition of all issued and outstanding common shares of Rise Israel. The Company also issued: (i) 406,308 incentive stock options (the “Replacement Options”) to a holder of options issued by Rise Israel, which were cancelled in connection with the RTO Transaction; (ii) 50,000 incentive stock options (together with the Replacement Options, the “Stock Options”) to a consultant of the Company; and (iii) 4,155,686 restricted share units (the “RSUs”) to certain directors, officers and consultants of the Company. The Stock Options and RSUs are subject to a statutory hold period of four months pursuant to applicable Canadian securities laws.

Rise has also received conditional listing approval on February 25, 2026 from the CSE for listing of the common shares in the capital of the Company (the “Common Shares”). Listing remains subject to Rise fulfilling certain customary CSE requirements.

Further to the closing of the RTO transaction, the Company entered into an escrow agreement dated March 4, 2026 among the Company, Endeavor Trust Corporation as transfer agent (“Endeavor”) and certain securityholders of the Company (the “Escrow Agreement”).

Copies of the Final Prospectus and the Escrow Agreement are available on the Company’s profile on SEDAR+, found at www.sedarplus.ca.

Further, Rise is also pleased to announce that the Escrow Release Conditions (as defined below) in connection with the private placement offering of 5,016,483 subscription receipts of the Company (the “Subscription Receipts“) for total gross proceeds of CAD$3,511,538.10 (the “Subscription Receipt Financing“) have been satisfied. The Company also issued an aggregate of 335,095 Common Shares to certain finders in connection with the Subscription Receipt Financing.

The Subscription Receipts were issued pursuant to a subscription receipt agreement, as amended (the “Subscription Receipt Agreement“) between the Company and Endeavor as subscription receipt agent. Pursuant to the Subscription Receipt Agreement, the proceeds from the Subscription Receipt Financing (the “Escrowed Funds“) were deposited in escrow with Endeavor pending satisfaction or waiver of the following conditions: (i) satisfaction of all conditions precedent to the RTO Transaction; and (ii) Rise having delivered an irrevocable direction to Endeavor confirming that item (i) has been satisfied (the “Escrow Release Conditions“).

Rise has delivered an irrevocable direction to Endeavor confirming that it has obtained a receipt for the Final Prospectus. The Escrow Release Conditions having been satisfied, the Escrowed Funds have been released to Rise and the Subscription Receipts automatically converted, for no additional consideration and with no further action by the holders thereof, into 5,016,483 Common Shares and 5,016,483 Common Share purchase warrants (“Warrants”), which will each entitle the holder thereof to acquire one Common Share at any time until September 4, 2027 for a price of $1.00 per Common Share.

Pursuant to the RTO Transaction, the shareholders of Rise Israel also received 9,331,785 contingent value rights (the “Contingent Rights”), each convertible into one Common Share upon the achievement of certain milestones, as more fully described in the Final Prospectus.

About Rise

Rise Nano Optics Ltd. is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented SPECTRAGUARD™ technology integrates nanomaterial innovation, ophthalmic research, and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

For more information, visit: www.risenanooptics.com

Investor Contacts:

Inas Said
Chief Executive Officer
Rise Nano Optics Ltd.
Email: inas.said@risenanooptics.com
Tel: +972 526977140

Danielle Shortall
Corporate Communications
Email: Danielle.shortall@risenanooptics.com
Tel: +1 (437) 226 0612

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward‐Looking Statements

This news release contains forward-looking statements relating to the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the trading of the Common Shares and the future plans and objectives of the Company, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

Readers are cautioned that that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the approval of the CSE to commence trading of the Common Shares. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.